Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bio-Path Holdings (BPTH) Stock Price & Analysis

BPTH Stock Chart & Stats

$0.00$0.00(0.00%)
At close: 10:18 AM EST
$0.02$0.03$0.04$0.058 Jun22 Jun6 Jul21 Jul3 Aug17 Aug31 Aug
Day’s Range
$0.01 - $0.03
52-Week Range
$0.01 - $0.11
Previous Close
$0.03
Volume
N/A
Average Volume (3M)
53.09K
Market Cap
$15.09K
Enterprise Value
$1.94M
Total Cash (Recent Filing)
$2,000
Total Debt (Recent Filing)
$520.00K
Price to Earnings (P/E)
―
Beta
-0.57
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Absolute Debt

Very low absolute debt limits near-term interest and refinancing pressure, preserving more flexibility than a highly leveraged clinical-stage company. This provides some balance-sheet support while BPTH funds research and development, although it does not offset the company’s negative equity position.

Reduced Cash Burn

The sharply lower cash outflow in 2025 indicates improved spending control and a reduced pace of cash consumption. If sustained, this could extend the company’s operating runway and reduce the frequency or size of external financing needs, even though cash generation remains negative.

Focused Oncology Platform

A focused RNAi oncology strategy and proprietary delivery technology provide a defined platform around which multiple cancer programs may be developed. Concentration in hematologic malignancies and other oncology indications can support specialized expertise and pipeline coherence, subject to clinical success.

Bears Say

No Commercial Revenue

The absence of commercial revenue shows that BPTH remains dependent on successful clinical development and future regulatory approval before establishing a recurring operating business. This leaves near-term financial performance driven by research spending rather than product demand or proven commercial traction.

Negative Equity And Asset Depletion

Negative equity and the steep reduction in total assets indicate substantial capital depletion and materially reduced financial flexibility. This weakens the company’s balance-sheet resilience, limits internal funding capacity, and increases dependence on obtaining additional capital to continue development activities.

Persistent Cash Outflows

Recurring negative operating and free cash flow means the business has not yet demonstrated self-funding economics. Continued development therefore depends on external financing over time, exposing shareholders to funding risk and potentially limiting the pace or scope of pipeline investment.

Bio-Path Holdings News

BPTH FAQ

What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $15.09K.
When is Bio-Path Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on Aug 18, 2026. The company reported -$0.088 earnings per share for the quarter.
Is Bio-Path Holdings overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.088 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Hedge funds hold Bio-Path Holdings shares: the largest hedge-fund position in Bio-Path Holdings is 71,862,051 shares, and hedge funds decreased their holdings by 2.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology